Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
PaperCitations, authors & open-access status
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,312 citations, 2014 year and green oa status.
1,312
Citations
2014
Year
green
OA Status